Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI)

Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI)

According to the data derived from several national and international registries, including SANI (Severe Asthma Network Italy), and considering the strong impact that frequent or regular use of oral corticosteroid has on quality of life (QoL) of severe asthmatics, as well as on the costs for managin...

书目详细资料
Main Authors:	Giorgio Walter Canonica, Francesco Blasi, Pierluigi Paggiaro, Gianenrico Senna, Giovanni Passalacqua, Antonio Spanevello, Stefano Aliberti, Diego Bagnasco, Marco Bonavia, Matteo Bonini, Luisa Brussino, Caterina Bucca, Maria F. Caiaffa, Cecilia Calabrese, Gianna Camiciottoli, Marco Caminati, Giovanna E. Carpagnano, Cristiano Caruso, Stefano Centanni, Maria E. Conte, Angelo G. Corsico, Lorenzo Cosmi, Maria T. Costantino, Nunzio Crimi, Simona D’Alò, Maria D'Amato, Stefano Del Giacco, Alessandro Farsi, Elisabetta Favero, Maria P. Foschino Barbaro, Gabriella Guarnieri, Giuseppe Guida, Manuela Latorre, Salvatore Lo Cicero, Carlo Lombardi, Luigi Macchia, Francesco Mazza, Francesco Menzella, Manlio Milanese, Marcello Montagni, Paolo Montuschi, Eleonora Nucera, Roberta Parente, Vincenzo Patella, Girolamo Pelaia, Laura Pini, Francesca Puggioni, Luisa Ricciardi, Fabio L.M. Ricciardolo, Luca Richeldi, Erminia Ridolo, Giovanni Rolla, Pierachille Santus, Nicola Scichilone, Giuseppe Spadaro, Andrea Vianello, Vittorio Viviano, Mona R. Yacoub, Maria C. Zappa, Enrico Heffler
格式:	文件
语言:	English
出版:	Elsevier 2020-10-01
丛编:	World Allergy Organization Journal
主题:	Severe asthma Biologics Oral corticosteroids Real-life Registr
在线阅读:	http://www.sciencedirect.com/science/article/pii/S1939455120303677

相似书籍

Patient and physician perspectives on biological treatment in severe asthma: a Severe Asthma Network Italy survey
由: Claudia Crimi, et al.
出版: (2023-11-01)

Nasal polyps impact in severe asthma patients: evidences from the SANI
由: Giorgio Walter Canonica, et al.
出版: (2020-08-01)

Economic impact of a more extensive use of FENO testing on the Italian population with asthma
由: Carla Rognoni, et al.
出版: (2023-06-01)

Asthma severity: the patient’s point of view
由: Gabriella Guarnieri, et al.
出版: (2024-12-01)

Is Bronchiectasis (BE) Properly Investigated in Patients with Severe Asthma? A Real-Life Report from Eight Italian Centers
由: Giovanna Elisiana Carpagnano, et al.
出版: (2023-10-01)

Clinical-economic impact of mepolizumab in patients with severe hypereosinophilic asthma
由: Diego Bagnasco, et al.
出版: (2020-08-01)

Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life
由: Diego Bagnasco, et al.
出版: (2021-02-01)

Severe asthma: One disease and multiple definitions
由: Diego Bagnasco, MD, PhD, et al.
出版: (2021-11-01)

Critical evaluation of asthma biomarkers in clinical practice
由: Giuseppe Guida, et al.
出版: (2022-10-01)

Biologics in Severe Eosinophilic Asthma: Three-Year Follow-Up in a SANI Single Center
由: Paolo Solidoro, et al.
出版: (2022-01-01)

Profiling severe asthma: Any relevance for age? An analysis from Severe Asthma Network Italy (SANI) cohort
由: Marco Caminati, MD, et al.
出版: (2024-08-01)

Phenotype overlap in the natural history of asthma
由: Fabio L.M. Ricciardolo, et al.
出版: (2023-05-01)

Minimal clinically important difference for asthma endpoints: an expert consensus report
由: Matteo Bonini, et al.
出版: (2020-06-01)

Long-Term Efficacy of Mepolizumab at 3 Years in Patients with Severe Asthma: Comparison with Clinical Trials and Super Responders
由: Diego Bagnasco, et al.
出版: (2023-08-01)

Manifesto on the overuse of SABA in the management of asthma: new approaches and new strategies
由: Giorgio Walter Canonica, et al.
出版: (2021-09-01)

Biologics as well as inhaled anti-asthmatic therapy achieve clinical remission: Evidence from the Severe Asthma Network in Italy (SANI)
由: Giorgio Walter Canonica, MD, et al.
出版: (2025-01-01)

Tezepelumab: patient selection and place in therapy in severe asthma
由: Francesco Menzella, et al.
出版: (2024-04-01)

Treatment strategies for asthma: reshaping the concept of asthma management
由: Alberto Papi, et al.
出版: (2020-08-01)

Omalizumab as add‐on therapy in a patient with severe asthma and OSA
由: Giulia Scioscia, et al.
出版: (2020-03-01)

Efficacy of Mepolizumab in patients with previous Omalizumab treatment failure: real life observation
由: Diego Bagnasco, et al.
出版: (2020-08-01)

The evidence on tiotropium bromide in asthma: from the rationale to the bedside
由: Dejan Radovanovic, et al.
出版: (2017-05-01)

Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps
由: Corrado Pelaia, et al.
出版: (2023-03-01)

Vascular remodeling and TSLP/angiogenin overexpression in severe mixed asthma
由: Francesca Bertolini, et al.
出版: (2025-02-01)

Erratum to: The evidence on tiotropium bromide in asthma: from the rationale to the bedside
由: Dejan Radovanovic, et al.
出版: (2017-06-01)

Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab
由: Erminia Ridolo, et al.
出版: (2020-10-01)

Brittle asthma
由: O. Toungoussova, et al.
出版: (2016-02-01)

Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study
由: Alessandra Vultaggio, et al.
出版: (2023-05-01)

Expression profiling of miRNA-145 and miRNA-338 in serum and sputum of patients with COPD, asthma, and asthma–COPD overlap syndrome phenotype
由: Lacedonia D, et al.
出版: (2017-06-01)

Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma
由: Giovanna Elisiana Carpagnano, et al.
出版: (2021-03-01)

SANI-Severe Asthma Network in Italy: a way forward to monitor severe asthma
由: G. Senna, et al.
出版: (2017-04-01)

Benralizumab in Patients With Severe Eosinophilic Asthma With and Without Chronic Rhinosinusitis With Nasal Polyps: An ANANKE Study post-hoc Analysis
由: Maria D'Amato, et al.
出版: (2022-05-01)

Predictors of reversible airway obstruction with omalizumab in severe asthma: a real-life study
由: Paolo Solidoro, et al.
出版: (2019-04-01)

The clinical profile of benralizumab in the management of severe eosinophilic asthma
由: Francesco Menzella, et al.
出版: (2016-12-01)

Positioning tezepelumab for patients with severe asthma: from evidence to unmet needs
由: Carlo Lombardi, et al.
出版: (2024-11-01)

The extracellular matrix of the lung and airway responsiveness in asthma
由: F.G. Salerno, et al.
出版: (2016-01-01)

Alexithymia and asthma: a systematic review
由: Orlando Silvestro, et al.
出版: (2023-08-01)

Very long-term data on patients with severe eosinophilic asthma treated with mepolizumab: a case series
由: Carlo Lombardi, et al.
出版: (2024-07-01)

“Characteristics of patients admitted to emergency department for asthma attack: a real-LIFE study”
由: Laura Losappio, et al.
出版: (2019-06-01)

Interleukin-5 in the Pathophysiology of Severe Asthma
由: Corrado Pelaia, et al.
出版: (2019-12-01)

Role of Leukotrienes and Leukotriene Modifiers in Asthma
由: Paolo Montuschi
出版: (2010-06-01)